AOD-9604 vs HGH for Fat Loss: What I Actually Saw After Using Both
For FormBlends, the useful starting point is not whether the internet is excited about it. It is whether the evidence, safety limits, prescription pathway, and follow-up plan are strong enough to support a real patient decision.
Last October, a friend named Derek in Austin showed me his latest DEXA scan. He’d been on AOD-9604 for ten weeks, paying about $180 a month out of pocket, and was expecting the kind of dramatic recomposition he’d seen in YouTube thumbnails. The scan showed a 0.6 percent reduction in total body fat. “I thought this was supposed to be the fat-burning part of growth hormone,” he said, sliding the printout across the table at a coffee shop on South Lamar. “Six hundred bucks for this?” His frustration is common, and it’s rooted in a marketing claim that deserves a proper autopsy.
The standard pitch for AOD-9604 goes something like this: it’s the fat-burning fragment of HGH (amino acid residues 176 through 191), giving you the lipolysis without the side effects. That description is technically grounded in the peptide’s origin story. But it overstates the practical comparison by a wide margin. I’ve used both compounds in different clinical contexts, and the gap between them is far bigger than the sales copy suggests.
Compliance frame. AOD-9604 is a research-stage peptide, not FDA-approved for any human indication. In the United States, it’s accessed through 503A compounding pharmacies under individual patient prescriptions based on prescriber judgment. Recombinant human growth hormone (somatropin) is FDA-approved for specific indications: pediatric growth failure, adult growth hormone deficiency confirmed by stimulation testing, AIDS wasting, and a few others. Use outside approved indications is not legally prescribable in the U.S. This is personal experience, not medical advice.
My History With Both Compounds
HGH. I did a six-month course of low-dose somatropin (0.4 IU per day) under an endocrinologist’s supervision after stim testing confirmed adult growth hormone deficiency consistent with a partial pituitary issue. The prescription was for the diagnosed deficiency. Fat loss was a secondary observation, not the goal.
AOD-9604. Two separate 12-week protocols of compounded AOD-9604, both prescribed by my physician and fulfilled through a 503A pharmacy. These were specifically targeting localized fat.
The contexts are different, and that matters. This isn’t a head-to-head comparison of “which melts fat faster in a healthy person,” because HGH is not legally available for that purpose. The real question is: what does each one actually do, and when is each tool appropriate?
What Six Months of Low-Dose HGH Looked Like
Over the somatropin course:
- IGF-1 rose from 78 to 188
- Fasting glucose held steady
- Body composition shifted meaningfully: total body fat dropped 4.1 percent, lean mass increased 1.4 pounds
- Visceral fat came down significantly
- Sleep got noticeably deeper, recovery improved, skin and connective tissue quality changed in subtle ways I didn’t expect
- Mild joint stiffness in months two and three, then it resolved on its own
- Energy was better, though hard to quantify
Those body composition changes were real. HGH at a clinical dose for a clinical indication is a serious metabolic intervention. The mechanism is broad, the effects are broad. It touches IGF-1 production, lipolysis, tissue repair, glucose handling. The whole system moves.
What 24 Weeks of AOD-9604 Looked Like
Across two 12-week protocols (separated by time, so 24 total weeks of exposure):
- IGF-1 unchanged
- Fasting glucose unchanged
- Body composition shifted modestly: total body fat down about 1.5 percent across both protocols combined
- Visceral fat down a small amount
- Subjective effects: basically nothing. No sleep changes, no recovery changes, no joint issues, no energy shifts. Clean.
Something is happening at the adipocyte level. The lipolysis signal appears to be present. But the magnitude of the effect is dramatically smaller than HGH. Like comparing a space heater to a furnace.
Why the Gap Is So Large
Growth hormone has at least four major effect domains in adults:
- Stimulating IGF-1 production in the liver
- Promoting lipolysis in adipose tissue
- Driving tissue repair and protein synthesis
- Broad metabolic effects on glucose and insulin signaling
AOD-9604, based on that C-terminal fragment (residues 176 to 191), appears to retain mainly the lipolytic effect, domain number two, without meaningfully engaging the other three. In practice, this means you’re getting a single channel of what HGH does, at presumably a fraction of the integrated magnitude. The body composition changes I saw reflect exactly that: modest, slow, limited to fat tissue, with nothing else moving.
Where the Marketing Falls Apart
Here’s the thing. The four most common AOD-9604 marketing claims range from “technically true but misleading” to “not supported.”
“Fat-burning effects of HGH without the side effects.” Half right. The side effect profile is cleaner because the broad HGH effects aren’t engaged. But the fat-burning effect at typical AOD-9604 doses is much, much smaller than clinical HGH. Calling it “the fat-burning effects of HGH” without mentioning the effect size gap is like advertising a bicycle as “transportation like a car, without the emissions.”
“Targeted spot reduction.” The published phase IIb data showed modest overall weight reduction. Some preclinical work hints at depot-selective effects, but the human evidence for true spot reduction is weak. Anyone promising you’ll lose the love handles specifically is extrapolating well past the data.
“Rapid fat loss in weeks.” Not what I saw. Not what the trial data shows. The effect curve is slow and subtle.
“Fat loss without growth hormone effects.” This one is mostly accurate at standard compounded doses. IGF-1 elevation is minimal. The clean lab profile is actually one of AOD-9604’s genuinely useful features.
Who Should Consider AOD-9604, and Who Shouldn’t
If you’re already relatively lean, your nutrition and training are genuinely dialed in (not just “pretty good,” actually dialed in), and you’re dealing with stubborn localized fat that won’t budge, AOD-9604 is a low-risk option that may produce gradual, modest improvement over months. Calibrate your expectations to the published data, not the before-and-after photos on someone’s Instagram.
If you need to lose 20 to 30 pounds, AOD-9604 is the wrong tool entirely. GLP-1 medications like semaglutide and tirzepatide are more effective by orders of magnitude. So is a sustained caloric deficit through nutrition. Spending money on AOD-9604 before those fundamentals are locked down is, frankly, a waste.
If you’re hoping for the kind of body composition shifts that HGH produces in deficiency states, AOD-9604 is not a substitute. The effects aren’t in the same category.
When HGH Is the Right Path
When clinical adult growth hormone deficiency is diagnosed by stimulation testing and the patient meets FDA-approved indication criteria. In that context, HGH is the correct intervention, and the body composition changes are part of the broader benefit of treating the underlying condition properly under specialist care, typically an endocrinologist.
Outside that indication, HGH is not legally prescribable in the United States for fat loss or general anti-aging purposes. Anyone marketing it otherwise is operating outside the regulatory framework, and the patient is absorbing legal risk, quality risk, and medical risk with no regulatory safety net.
What I’d Actually Recommend (Ranked)
For the specific use case of stubborn localized fat in an otherwise healthy adult:
- Optimize nutrition and training first. Most localized fat issues respond to a tighter version of the basics. This is boring advice. It’s also correct.
- Ask yourself whether intervention is actually warranted. Localized fat is an aesthetic concern, not a health problem. The distinction matters when you’re weighing costs, injections, and risk.
- If still wanting a peptide adjunct, AOD-9604 is reasonable given the low side-effect profile and modest effect size. Go in with realistic expectations.
- If you suspect genuine GH deficiency, work with an endocrinologist on proper diagnostic workup and, if confirmed, the appropriate clinical pathway for somatropin.
- Do not pursue HGH off-label for general fat loss. The risk profile, the legal exposure, and the quality assurance problems do not justify it.
Sourcing and Practical Notes
My AOD-9604 prescriptions have been fulfilled through FormBlends, a compounded telehealth pharmacy working with licensed 503A compounding pharmacies. Lot labeling has been consistent across both protocols. Beyond-use dating was clear. Sterility statements available on request.
For HGH, the appropriate path is a major pharmacy chain with insurance coverage for the FDA-approved indication, prescribed by an endocrinologist or specialist managing the underlying deficiency. There is no shortcut here that’s worth taking.
The Boring Truth
HGH is a powerful, broad metabolic intervention that produces significant body composition changes when used appropriately for diagnosed adult GH deficiency under specialist care.
AOD-9604 is a much narrower tool. Modest fat loss, clean side effect profile, useful as an adjunct in specific situations where everything else is already in place. My opinion: it has a role, but it’s a supporting role, not a lead.
The two are not interchangeable. The marketing that positions AOD-9604 as a side-effect-free HGH substitute is misleading about the effect size, misleading about the speed, and misleading about the regulatory context. For the stubborn-fat use case in an otherwise healthy adult, AOD-9604 is worth considering if your expectations match reality. It is not a replacement for growth hormone therapy, and growth hormone therapy is not a legitimate fat-loss tool for someone without a diagnosed approved indication.
AOD-9604 is not FDA-approved for any human indication. HGH (somatropin) is FDA-approved for specific indications; use outside those indications is not legally prescribable in the United States. Compounded AOD-9604 is prepared by licensed 503A pharmacies for individual patients based on prescriber clinical judgment. Personal experience, not medical advice.
